Levetiracetam Brillpharma

Levetiracetam, the active ingredient in Levetiracetam Brillpharma, is an antiepileptic presented as an oral tablet for oral use. It treats partial, generalized tonic‑clonic and myoclonic seizures in patients who require seizure control.

GNH USA supplies Levetiracetam Brillpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is used to control seizures across several epilepsy syndromes.

- Partial seizures: reduces the frequency of focal onset seizures. - Generalized tonic‑clonic seizures: decreases the occurrence of bilateral convulsive episodes. - Myoclonic seizures: lessens rapid, involuntary muscle jerks.

Levetiracetam may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness - Fatigue - Somnolence - Headache - Irritability - Nausea

Serious or Rare Side Effects: - Severe allergic reactions (e.g., anaphylaxis) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Blood dyscrasias such as neutropenia - Suicidal thoughts or behavior - Severe skin rash - Hepatic dysfunction

When prescribing levetiracetam, clinicians should consider several safety aspects. - Renal impairment: dose may need adjustment based on creatinine clearance. - Hepatic function: monitor liver enzymes in patients with existing liver disease. - Psychiatric history: observe for mood changes, depression, or suicidal ideation. - Concomitant CNS depressants: may enhance sedation or dizziness. - Pregnancy considerations: use only if potential benefit justifies potential risk. - Store at room temperature: keep in the original container, protect from moisture.

Levetiracetam can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Carbamazepine: enzyme induction may lower levetiracetam plasma levels. - Phenytoin: strong inducer that can decrease levetiracetam exposure. - Phenobarbital: reduces levetiracetam concentrations through hepatic enzyme activation.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam levels modestly. - Fluconazole: potential mild increase in exposure. - Oral contraceptives: monitor for possible reduced contraceptive effectiveness.